Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2236 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2236 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase III Oncology
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Adding CGT9486 to sunitinib compared to sunitinib alone for gastrointestinal stromal tumour patients who've failed or are intolerant to imatinib.
22 May 2026 NCT05208047
active not recruiting Phase III Diabetes / Metabolic
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ – CVOT)
Survodutide injection reduces cardiovascular events in overweight or obese adults with heart or kidney disease compared to placebo.
22 May 2026 NCT06077864
● Recruiting Respiratory / COPD / Asthma
The CATALINA Study
What is being tested: CATALINA is collecting standardised longitudinal clinical data and biological samples from COPD patients across multiple European centres to identify patterns…
22 May 2026 NCT05008081
● Recruiting Phase I Oncology
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
What is being tested: OKN4395, a novel investigational drug, is being evaluated as monotherapy and in combination with pembrolizumab (an established PD-1 checkpoint inhibitor)…
22 May 2026 NCT06789172
● Recruiting Phase I Oncology
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Drug being tested: DS9051b, a first-in-human (FIH) investigational agent, is being evaluated for safety, tolerability, and early efficacy signals in two aggressive malignancies: advanced/metastatic…
22 May 2026 NCT07189403
● Recruiting Phase I Oncology
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Treatment being tested: Patritumab deruxtecan (MK-1022), a HER2-targeted antibody-drug conjugate, either alone or in combination with other anticancer agents in patients with HER2-positive unresectable…
22 May 2026 NCT06686394
● Recruiting Phase II Oncology
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Treatment Being Tested: Datopotamab deruxtecan (Dato-DXd) monotherapy versus Dato-DXd combined with the immunotherapy agent durvalumab in patients with PD-L1-negative metastatic triple-negative breast cancer (TNBC).…
22 May 2026 NCT06954480
● Recruiting Phase III Oncology
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
What is being tested: Tabelecleucel, an EBV-specific T-cell immunotherapy, is being evaluated for treating EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in solid organ and…
22 May 2026 NCT03394365
● Recruiting Cardiology / Cardiovascular
Mechanism of Chronic Pain in Patients With IBD
What is being tested: This trial investigates the underlying biological mechanisms causing chronic abdominal pain in IBD patients, particularly why pain persists even during…
22 May 2026 NCT04995224
● Recruiting Phase I Cardiology / Cardiovascular
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
What is being tested: Belantamab, an unconjugated antibody targeting BCMA (B-cell maturation antigen), is being evaluated as both a monotherapy and in combination regimens…
22 May 2026 NCT05714839
● Recruiting Cardiology / Cardiovascular
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
What is being tested: The PEACH trial uses positron emission tomography (PET) imaging to evaluate whether Camzyos (mavacamten), a cardiac myosin inhibitor, reduces myocardial…
22 May 2026 NCT07120776
● Recruiting Cardiology / Cardiovascular
Biofeedback Intervention for Paroxysmal Atrial Fibrillation
What is being tested: A biofeedback intervention system designed to enable daily monitoring of atrial fibrillation (AF) episodes and physical activity levels in patients…
22 May 2026 NCT07454317
● Recruiting Phase I Oncology
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Drug Being Tested: INBRX-109 is a first-in-human recombinant humanized tetravalent antibody targeting death receptor 5 (DR5), designed to trigger apoptosis in cancer cells through…
22 May 2026 NCT03715933
active not recruiting Cardiology / Cardiovascular
FARAPULSE Workflow Assessment Registry
Registry examining clinical workflows and outcomes when using pulsed field ablation to treat atrial fibrillation in routine practice settings.
20 May 2026 NCT06656884
active not recruiting Phase I Oncology
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Early-stage safety and dosage trial of new anti-CCR8 antibody BAY3375968 alone or combined with pembrolizumab in advanced solid tumours.
20 May 2026 NCT05537740
● Recruiting
Assessing the Efficacy of a Song to Improve Body Appreciation Among Young Children
A song about body confidence was tested in 4-6 year-old UK children to see if it improves how they feel about their bodies.
20 May 2026 NCT07586852
active not recruiting Phase II
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Trial comparing two drug combinations for newly diagnosed mantle cell lymphoma, measuring minimal disease status at six months.
20 May 2026 NCT04802590
active not recruiting Oncology
Contrast-Free Magnetic Resonance Imaging for Breast Disease
MRI without contrast dye can accurately diagnose breast cancer in women at risk or with suspected disease.
20 May 2026 NCT05006196
● Recruiting Neurology
The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer’s Disease (CoCoA-PAD)
What is being tested: Development and evaluation of CoCoA-PAD, a computerised cognitive assessment tool designed to identify individuals in the preclinical stages of Alzheimer's…
20 May 2026 NCT07598617
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
What is being tested: Adagrasib (MRTX849), a KRAS G12C inhibitor, evaluated as monotherapy and combined with pembrolizumab (anti-PD-L1 immunotherapy) in patients with advanced non-small…
20 May 2026 NCT04613596
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
What is being tested: Adagrasib (MRTX849), a targeted KRAS G12C inhibitor, is being evaluated as monotherapy and in combination with the immunotherapy pembrolizumab in…
20 May 2026 NCT04613596
● Recruiting Phase I Respiratory / COPD / Asthma
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
What is being tested: XTMAB-16, a novel therapeutic agent, is being evaluated in a phase 1b/2 study to assess its safety, tolerability, and efficacy…
20 May 2026 NCT05890729
● Recruiting Phase I Respiratory / COPD / Asthma
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
What is being tested: XTMAB-16, an investigational monoclonal antibody, is being evaluated in a phase 1b/2 study as a potential new treatment for pulmonary…
20 May 2026 NCT05890729
● Recruiting Phase II Cardiology / Cardiovascular
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
What is being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated for efficacy and safety in treating severe active GPA (Granulomatosis with…
20 May 2026 NCT06868290
● Recruiting Phase II Cardiology / Cardiovascular
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Treatment being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated against a comparator treatment in patients with severe active GPA or MPA—rare…
20 May 2026 NCT06868290
● Recruiting Cardiology / Cardiovascular
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
What is being tested: Convergent ablation (combining epicardial and endocardial approaches) plus left atrial appendage isolation using the LARIAT procedure, compared to standard endocardial…
20 May 2026 NCT06165510
● Recruiting Cardiology / Cardiovascular
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
What is being tested: Convergent ablation (combining epicardial and endocardial approaches) plus left atrial appendage isolation using the LARIAT procedure, compared to standard endocardial…
20 May 2026 NCT06165510
● Recruiting Cardiology / Cardiovascular
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
What is being tested: Collection of high-resolution ECG data and patient insights to build a comprehensive ECG library that will support future research into…
20 May 2026 NCT06809686
● Recruiting Cardiology / Cardiovascular
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
What is being tested: Creation of a high-resolution ECG data library paired with patient-reported insights to support future cardiovascular research and improve understanding of…
20 May 2026 NCT06809686
● Recruiting Cardiology / Cardiovascular
Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk
What is being tested: The Heartfelt device, a non-invasive 3D imaging system that passively monitors foot and lower leg volume to detect early fluid…
20 May 2026 NCT07067658
● Recruiting Phase III Oncology
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Treatment being tested: Golcadomide combined with rituximab (Golca + R) versus investigator's choice treatment in patients with relapsed/refractory follicular lymphoma, evaluated in a Phase…
20 May 2026 NCT06911502
● Recruiting Phase III Oncology
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
What is being tested: Golcadomide combined with rituximab (Golca + R) versus standard investigator-selected treatment in patients with relapsed/refractory follicular lymphoma, evaluating efficacy and…
20 May 2026 NCT06911502
● Recruiting Phase III Oncology
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
What is being tested: Puxitatug samrotecan (AZD8205), a B7-H4-targeted therapy, versus standard chemotherapy (doxorubicin or paclitaxel) in patients with advanced/metastatic endometrial cancer that has…
20 May 2026 NCT07044336
● Recruiting Phase III Oncology
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Treatment being tested: Puxitatug samrotecan (AZD8205), a novel B7-H4-directed antibody-drug conjugate, compared against standard chemotherapy (doxorubicin or paclitaxel) in a Phase III randomized trial…
20 May 2026 NCT07044336
● Recruiting Phase II Oncology
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Intervention Being Tested: Radspherin® (a single intraperitoneal injection) is being evaluated as an adjunct to standard neoadjuvant chemotherapy and interval debulking surgery in patients…
20 May 2026 NCT06504147
● Recruiting Phase II Oncology
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
What is being tested: Radspherin® (a single intraperitoneal injection) is being evaluated for efficacy and safety in patients with primary advanced high-grade serous or…
20 May 2026 NCT06504147
● Recruiting Phase II Oncology
Visugromab in Cachexia International Trial
What is being tested: Visugromab, a novel therapeutic agent, is being evaluated for efficacy and safety in managing cancer-associated cachexia (unintended weight loss) across…
20 May 2026 NCT07112196
● Recruiting Phase II Oncology
Visugromab in Cachexia International Trial
What is being tested: Visugromab, a novel therapeutic agent, is being evaluated for safety and efficacy in treating cancer-associated cachexia (unintended weight loss) across…
20 May 2026 NCT07112196
● Recruiting Phase III Oncology
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Treatment being tested: Surovatamig (AZD0486), a novel agent, combined with rituximab versus standard immunochemotherapy regimens (investigator's choice of three options) in previously untreated follicular…
20 May 2026 NCT06549595
● Recruiting Phase III Oncology
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
What is being tested: Surovatamig (AZD0486), a novel agent, combined with rituximab versus standard immunochemotherapy regimens (investigator's choice of 3 options) in treatment-naive follicular…
20 May 2026 NCT06549595
active not recruiting Phase III
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Atogepant tablets tested for treating individual migraine attacks in adults; currently approved only for prevention.
19 May 2026 NCT06241313
active not recruiting Phase II
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Testing whether VHB937 drug slows early ALS progression compared to placebo over 40 weeks, then all patients receive active treatment.
19 May 2026 NCT06643481
● Recruiting Phase III Diabetes / Metabolic
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Tirzepatide with lifestyle changes reduced weight and improved heart disease risk factors in obese teenagers with related health problems.
19 May 2026 NCT06439277
● Recruiting Phase III
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Trial testing atogepant tablets versus placebo for preventing chronic migraine in teenagers aged 12-17 years over 12 weeks.
19 May 2026 NCT06810505
● Recruiting Phase III Diabetes / Metabolic
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
AMAZE 12 Summary Trial testing whether weekly injections of NNC0487-0111 help people maintain weight loss compared to placebo.
19 May 2026 NCT07503210
active not recruiting Phase III Cardiology / Cardiovascular
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Long-term safety and effectiveness study of inhaled seralutinib for pulmonary hypertension patients who previously completed earlier trials.
19 May 2026 NCT06274801
active not recruiting Phase III Oncology
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Trial testing whether adding darolutamide to hormone therapy improves survival in men with early prostate cancer recurrence after surgery or radiotherapy.
19 May 2026 NCT05794906
active not recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
persevERA Trial Summary A new breast cancer drug (giredestrant) plus palbociclib compared to standard treatment (letrozole) plus palbociclib in advanced hormone-receptor-positive breast cancer.
19 May 2026 NCT04546009
● Recruiting Oncology
EVERiST: Impact of Image Detected Accessory Pudendal Artery on Erection Recovery After Nerve Sparing Prostatectomy
What is being tested: The EVERiST trial investigates whether pre-operative imaging detection of accessory pudendal arteries influences erectile function recovery following nerve-sparing radical prostatectomy…
19 May 2026 NCT07597798
● Recruiting Phase I Oncology
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Treatment being tested: Telisotuzumab adizutecan (an anti-HER3 antibody-drug conjugate) combined with a PD-1 immune checkpoint inhibitor in treatment-naïve advanced/metastatic non-squamous NSCLC without actionable genomic…
19 May 2026 NCT06772623